Terms: = Kidney tumors AND HOXD13, SPD, 3239, P35453, HOX4I
20 results:
1. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Ueda K; Uemura K; Ito N; Sakai Y; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Nishihara K; Nakiri M; Suekane S; Ogasawara S; Yano H; Igawa T
Curr Oncol; 2024 Mar; 31(4):1701-1712. PubMed ID: 38668032
[TBL] [Abstract] [Full Text] [Related]
2. Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
3. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
Singla N; Nirschl TR; Obradovic AZ; Shenderov E; Lombardo K; Liu X; Pons A; Zarif JC; Rowe SP; Trock BJ; Hammers HJ; Bivalacqua TJ; Pierorazio PM; Deutsch JS; Lotan TL; Taube JM; Ged YMA; Gorin MA; Allaf ME; Drake CG
Sci Rep; 2024 Jan; 14(1):1458. PubMed ID: 38228729
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab.
Wakita N; Hinata N; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M
Anticancer Res; 2023 Feb; 43(2):841-847. PubMed ID: 36697079
[TBL] [Abstract] [Full Text] [Related]
5. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma.
Nguyen MV; Walia A; Saidian A; Puri D; Meagher MF; Hakimi K; Tanaka H; Patil D; Yasuda Y; Saito K; Dhanji S; Cerrato C; Narasimhan R; Perry J; Master V; Fujii Y; Derweesh IH
BJU Int; 2023 Feb; 131(2):219-226. PubMed ID: 35876044
[TBL] [Abstract] [Full Text] [Related]
6. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.
Keber CU; Derigs M; Schultz C; Wegner M; Lingelbach S; Wischmann V; Hofmann R; Denkert C; Hegele A; Hänze J
Cancer Immunol Immunother; 2022 Oct; 71(10):2381-2389. PubMed ID: 35184226
[TBL] [Abstract] [Full Text] [Related]
7. Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863
[TBL] [Abstract] [Full Text] [Related]
8. kidney tumor diffusion-weighted magnetic resonance imaging derived ADC histogram parameters combined with patient characteristics and tumor volume to discriminate oncocytoma from renal cell carcinoma.
van Oostenbrugge TJ; Spenkelink IM; Bokacheva L; Rusinek H; van Amerongen MJ; Langenhuijsen JF; Mulders PFA; Fütterer JJ
Eur J Radiol; 2021 Dec; 145():110013. PubMed ID: 34768055
[TBL] [Abstract] [Full Text] [Related]
9. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
[TBL] [Abstract] [Full Text] [Related]
10. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract] [Full Text] [Related]
11. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Bando Y; Hinata N; Omori T; Fujisawa M
BMJ Open; 2019 Dec; 9(12):e030522. PubMed ID: 31826889
[TBL] [Abstract] [Full Text] [Related]
12. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract] [Full Text] [Related]
13. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract] [Full Text] [Related]
14. Soluble Ligand of the Immune Checkpoint Receptor (spd-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
[TBL] [Abstract] [Full Text] [Related]
15. Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal Cancers.
Loginov VI; Dmitriev AA; Senchenko VN; Pronina IV; Khodyrev DS; Kudryavtseva AV; Krasnov GS; Gerashchenko GV; Chashchina LI; Kazubskaya TP; Kondratieva TT; Lerman MI; Angeloni D; Braga EA; Kashuba VI
PLoS One; 2015; 10(5):e0123369. PubMed ID: 25961819
[TBL] [Abstract] [Full Text] [Related]
16. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract] [Full Text] [Related]
17. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity.
Elhag OA; Hu XJ; Wen-Ying Z; Li X; Yuan YZ; Deng LF; Liu DL; Liu YL; Hui G
Asian Pac J Cancer Prev; 2012; 13(8):4031-6. PubMed ID: 23098512
[TBL] [Abstract] [Full Text] [Related]
18. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D.
Samukawa T; Hamada T; Uto H; Yanagi M; Tsukuya G; Nosaki T; Maeda M; Hirano T; Tsubouchi H; Inoue H
BMC Pulm Med; 2012 Sep; 12():55. PubMed ID: 22963039
[TBL] [Abstract] [Full Text] [Related]
19. [tumors showing perivascular epithelioid cell differentiation: a clinicopathologic study of 39 cases].
Luo DL; Liu YH; Zhuang HG; Luo XL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2909-13. PubMed ID: 18261305
[TBL] [Abstract] [Full Text] [Related]
20. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
Pihie AH; Stanslas J; Din LB
Anticancer Res; 1998; 18(3A):1739-43. PubMed ID: 9673398
[TBL] [Abstract] [Full Text] [Related]
